{"DataElement":{"publicId":"2186022","version":"1","preferredName":"Cytochrome P450 3A4 Inhibition Induction Medication Administration Ind-2","preferredDefinition":"the yes/no indicator for administration of a medication that either inhibits or induces CYP3A4 (induced primarily in liver by glucocorticoids, drugs, pesticides, and carcinogens and encoded by human CYP3A4 Gene (Cytochrome P450 IIIA Subfamily), whose activity seems a key predictor of drug responsiveness and toxicity.","longName":"CYP3A4_MEDS_ADM_IND2","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2183335","version":"1","preferredName":"Cytochrome P450 3A4 Inhibition Induction Medication Administration","preferredDefinition":"information related to the administration of a medication that either inhibits or induces CYP3A4 (induced primarily in liver by glucocorticoids, drugs, pesticides, and carcinogens and encoded by human CYP3A4 Gene (Cytochrome P450 IIIA Subfamily), whose activity seems a key predictor of drug responsiveness and toxicity.","longName":"MEDS_ADMIN","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2944365","version":"1","preferredName":"Cytochrome P450 3A4 Inhibition Induction Medication","preferredDefinition":"Induced primarily in liver by glucocorticoids, drugs, pesticides, and carcinogens and encoded by human CYP3A4 Gene (Cytochrome P450 IIIA Subfamily), Cytochrome P450 3A4 is a 502-amino acid 57.3-kD membrane-bound ER heme-thiolate monooxygenase. CYP3A4 is involved in an NADPH-dependent electron transport pathway and phase I oxidative metabolism of carcinogens, steroids, fatty acids, and xenobiotics, as well as bioactivation of aflatoxin B(1) to a genotoxic derivative. Activity seems a key predictor of drug responsiveness and toxicity. (from LocusLink, Swiss-Prot, OMIM, and NCI):The interference with or prevention of an action or response even though the stimulus for that action or response is present.:The act of bringing about something.:biologically active substance, including those intended for use in diagnosis, treatment, or prevention of disease or other abnormalities, for the relief of suffering, or control or improvement of a physical or mental state; includes biological products.","longName":"C17573:C42791:C61367:C459","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytochrome P450 3A4","conceptCode":"C17573","definition":"Cytochrome P450 3A4 (503 aa, ~57 kDa) is encoded by the human CYP3A4 gene. This protein is involved in the oxidation of steroids, fatty acids and xenobiotics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Inhibition","conceptCode":"C42791","definition":"The interference with or prevention of an action or response even though the stimulus for that action or response is present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Induction","conceptCode":"C61367","definition":"The act of bringing about something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Medication","conceptCode":"C459","definition":"A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74324BC5-F7EB-F184-E040-BB89AD4313FF","latestVersionIndicator":"Yes","beginDate":"2009-09-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-09-22","modifiedBy":"ONEDATA","dateModified":"2009-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177666","version":"1","preferredName":"Administration","preferredDefinition":"The act of administration.","longName":"Administration","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Administration","conceptCode":"C25409","definition":"The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-516E-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D8AC3921-40CB-20B9-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-04-22","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-04-22","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811909","version":"1","longName":"Leukemia","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"},{"publicId":"2811954","version":"1","longName":"Eligibility Criteria","context":"CTEP"}]},{"publicId":"2008594","version":"2.31","longName":"Trial Type Usages (CDE Disease Committees)","context":"CTEP","ClassificationSchemeItems":[{"publicId":"10000362","version":"1","longName":"AML Prev Untreated","context":"CTEP"}]},{"publicId":"2008608","version":"1","longName":"Phase","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811890","version":"1","longName":"Phase III","context":"CTEP"}]},{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"10000276","version":"1","longName":"GOG-0283","context":"NRG"},{"publicId":"4104930","version":"1","longName":"GOG-0283","context":"NRG"},{"publicId":"10000275","version":"1","longName":"GOG-0283","context":"NRG"},{"publicId":"4104940","version":"1","longName":"GOG-0268","context":"NRG"},{"publicId":"4104938","version":"1","longName":"GOG-0254","context":"NRG"}]}],"AlternateNames":[{"name":"SWOG","type":"USED_BY","context":"SWOG"},{"name":"CYP3A4","type":"OID, SWOG","context":"SWOG"},{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"CYP3A4_MEDS_ADM_IND2","type":"USED_BY","context":"NRG"},{"name":"CYP3A4_MEDS_ADM_IND2","type":"USED_BY","context":"Alliance"},{"name":"CYP3A4_MEDS_ADM_IND2","type":"USED_BY","context":"CITN"},{"name":"Theradex","type":"USED_BY","context":"Theradex"},{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"CYP3A4 inhibitor/inducer","type":"Preferred Question Text","description":"CYP3A4 inhibitor/inducer","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Is the patient on medications classified as CYP3A4 inducers?","url":null,"context":"CTEP"},{"name":"CRF Text3","type":"Alternate Question Text","description":"Receiving any medications or substances that are strong or moderate inhibitors or inducers of CYP450 3A4. \r\n-\tUse of the following strong or moderate inhibitors are prohibited <=7 days prior to registration:\r\nStrong Inhibitors of CYP3A4:\r\no\tIndinavir\r\no\tNelfinavir\r\no\tRitonavir\r\no\tClarithromycin\r\no\tItraconazole\r\no\tKetoconazole\r\no\tNefazodone\r\no\tSaquinavir\r\no\tTelithromycin\r\nModerate Inhibitors of CYP3A4\r\no\tAprepitant\r\no\tErythromycin\r\no\tFluconazole\r\no\tGrapefruit juice\r\no\tVerapamil\r\no\tDiltiazem\r\n","url":null,"context":"CTEP"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Has treatment with a CYP3A4 inducer or inhibitor enzyme been discontinued for at least 2 weeks prior to study entry?","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Prior chronic concomitant treatment of strong CYP3A4 inducers or inhibitors","url":null,"context":"CTEP"},{"name":"ABTC Question Text","type":"Alternate Question Text","description":"Is the patient on drugs known to be moderate or potent inhibitors/inducers of CYP3A4, sensitive substrates of CYP3A4, or substrates of CYP3A4 with narrow therapeutic windows?","url":null,"context":"CTEP"},{"name":"NRG_CRF Text","type":"Alternate Question Text","description":"Is the patient on concomitant medications that are STRONG inducers or inhibitors of the CYP3A4 enzyme?","url":null,"context":"NRG"},{"name":"CRF Text 5","type":"Alternate Question Text","description":"Currently receiving therapy with a potent CYP3A4 inducer or inhibitor (see list in protocol, Appendix G). Patients may enter screening when therapy with the potent inhibitor or induce is completed.","url":null,"context":"CTEP"},{"name":"CRF text 2","type":"Alternate Question Text","description":"Subjects who are currently receiving therapy with a potent CYP3A4 inducer or inhibitor. Subjects may enter screening when therapy with the potent inhibitor or inducer is completed.","url":null,"context":"CTEP"},{"name":"CYP3A4 inhibitor/inducer","type":"Alternate Question Text","description":"Has patient taken any strong CYP3A4 inhibitors and/or strong CYP3A4 inducers?","url":null,"context":"SWOG"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Is patient receiving concomitant medications with strong inhibitors or inducers of CYP3A4?","url":null,"context":"Theradex"},{"name":"COG_CRF_TEXT_6","type":"Alternate Question Text","description":"Is patient receiving indicated CYP3A4 agents","url":null,"context":"COG"},{"name":"CRF Text 7","type":"Alternate Question Text","description":"Prior CYP3A4 inhibitor treatment?","url":null,"context":"Alliance"},{"name":"CRF Text6","type":"Alternate Question Text","description":"Prior CYP3A4 inducer treatment?","url":null,"context":"Alliance"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Does patient receive concomitant administration of a strong inhibitor and/or inducer of CYP3A4?","url":null,"context":"Theradex"},{"name":"CRF Text 8","type":"Alternate Question Text","description":"Has the patient had treatment with strong inhibitors or inducers of CYP3A within 14 days of registration?","url":null,"context":"CTEP"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Has patient received drugs that are strong inducers or inhibitors of CYP3A4 within 7 days prior to study enrollment?","url":null,"context":"COG"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"Does the patient have concomitant use of known strong CYP3A4 inhibitors (e.g., itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g., ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil)?","url":null,"context":"NRG"},{"name":"CRF Text9","type":"Alternate Question Text","description":"Chronic concomitant treatment with strong inducer of CYP3A4?","url":null,"context":"Alliance"},{"name":"NRG_eCRF_Text_1","type":"Alternate Question Text","description":"Were potent CYP3A4 inhibitors or inducers discontinued prior to starting treatment?","url":null,"context":"NRG"},{"name":"CRF Text10","type":"Alternate Question Text","description":"Chronic concomitant treatment with a strong CYP3A4 inducer?","url":null,"context":"Alliance"},{"name":"CRF Text11","type":"Alternate Question Text","description":"Prior treatment with strong or moderate CYP3A4 inducers or inhibitors?","url":null,"context":"Alliance"},{"name":"CRF Text12","type":"Alternate Question Text","description":"Prior Treatment with Strong or Moderate CYP3A4 Inducers or Inhibitors","url":null,"context":"Alliance"},{"name":"CRF Text13","type":"Alternate Question Text","description":"Prior Treatment with CYP3A4 Inducers or Inhibitors","url":null,"context":"Alliance"},{"name":"Has the patient received moderate to strong CYP3A4 inhibitors and inducers within 7 days prior to study enrollment?","type":"Alternate Question Text","description":"Has the patient received moderate to strong CYP3A4 inhibitors and inducers within 7 days prior to study enrollment?","url":null,"context":"COG"},{"name":"NRG_eCRF_Text_2","type":"Alternate Question Text","description":"Has the patient had treatment with strong CYP3A inhibitors or strong CYP3A inducers within 2 weeks or 5 drug-elimination half-lives, whichever is longer, prior to registration?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_3","type":"Alternate Question Text","description":"Has the patient had treatment with strong and moderate inhibitors or inducers of CYP3A within 14 days of Step 2 registration?","url":null,"context":"NRG"},{"name":"CRF TEXT 1","type":"Alternate Question Text","description":"Has the patient had treatment with strong CYP2C8 or CYP3A4 inhibitors or inducers within 14 days or 5 drug-elimination half-lives, whichever is longer prior to registration?","url":null,"context":"NRG"},{"name":"CRF Text14","type":"Alternate Question Text","description":"Was the last day of strong inducer of CYP3A4 >= 14 days or >= 5 half-lives prior to registration?","url":null,"context":"Alliance"},{"name":"CRF text15 - Alliance","type":"Alternate Question Text","description":"Prior strong CYP3A4 inhibitors treatment?","url":null,"context":"Alliance"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Has the patient received strong CYP3A4 inducers or strong CYP3A4 inhibitors?","url":null,"context":"COG"},{"name":"COG CRF Text 3","type":"Alternate Question Text","description":"Is patient currently receiving moderate or strong CYP3A4 Inhibitors or Inducers, another investigational drug, anti-cancer agent, or anti-GHVD agent?","url":null,"context":"COG"},{"name":"COG CRF Text 4","type":"Alternate Question Text","description":"Is patient currently receiving moderate or strong CYP3A4 Inhibitors or Inducers, P-glycoprotein (P-gp) inhibitors or inducers, another investigational drug, anti-cancer agent, or anti-GHVD agent?","url":null,"context":"COG"}],"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"DFE9731B-83C1-726F-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-07-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-07-23","modifiedBy":"KUMMEROA","dateModified":"2023-06-08","changeDescription":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":"2023.6.8 AQT added per ticket request CADSR0002507. ak 2023.3.6 AQT added per ticket request CADSR0002119. ak 2023.1.4 AQT added per ticket request CADSR0001862. ak 9/6/2022: added AQT for Alliance.wz","unresolvedIssues":null,"deletedIndicator":"No"}}